(RNAC) Cartesian Therapeutics - Ratings and Ratios
CAR-T, mRNA, Autoimmune, BCMA, Clinical Trials
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 81.2% |
| Value at Risk 5%th | 128% |
| Relative Tail Risk | -4.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.96 |
| Alpha | -89.31 |
| CAGR/Max DD | -0.50 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.359 |
| Beta | 1.913 |
| Beta Downside | 1.999 |
| Drawdowns 3y | |
|---|---|
| Max DD | 88.27% |
| Mean DD | 57.57% |
| Median DD | 63.65% |
Description: RNAC Cartesian Therapeutics October 27, 2025
Cartesian Therapeutics (NASDAQ: RNAC) is a clinical-stage biotech focused on autologous mRNA-based CAR-T therapies targeting B-cell maturation antigen (BCMA) for autoimmune indications, with its lead candidate Descartes-08 currently in a Phase 2b trial for generalized myasthenia gravis, systemic lupus erythematosus, and juvenile dermatomyositis (rare-pediatric-disease designation). Descartes-15, a second anti-BCMA mRNA CAR-T, is being positioned for relapsed/refractory multiple myeloma, expanding the company’s pipeline beyond autoimmune disease.
Key performance indicators as of Q2 2024 include a cash runway of roughly $120 million, a burn rate of ~$30 million per quarter, and enrollment of 45 patients in the Descartes-08 Phase 2b study-metrics that together set the timeline for a potential read-out by early 2025. The company’s R&D spend has risen 18 % YoY, reflecting accelerated pre-clinical work on Descartes-15.
Sector-wide, the mRNA therapeutic market is projected to grow at a CAGR of ~15 % through 2030, driven by rapid platform adoption post-COVID-19 and expanding payer acceptance of cell-based therapies. However, the high cost of autologous manufacturing and uncertain reimbursement pathways for autoimmune CAR-T treatments remain material risk factors.
For a deeper, data-driven assessment of RNAC’s valuation assumptions and scenario analysis, you may find the research tools on ValueRay useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-48.0m TTM) > 0 and > 6% of Revenue (6% = 65.5k TTM) |
| FCFTA -0.18 (>2.0%) and ΔFCFTA -7.86pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 12.2k% (prev 433.3%; Δ 11.8kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.17 (>3.0%) and CFO -63.2m <= Net Income -48.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.67 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (26.0m) change vs 12m ago 21.10% (target <= -2.0% for YES) |
| Gross Margin -1073 % (prev 98.36%; Δ -1171 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.26% (prev 10.53%; Δ -10.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -12.41 (EBITDA TTM -49.0m / Interest Expense TTM -4.18m) >= 6 (WARN >= 3) |
Altman Z'' -6.76
| (A) 0.36 = (Total Current Assets 147.3m - Total Current Liabilities 13.8m) / Total Assets 372.7m |
| (B) -1.96 = Retained Earnings (Balance) -729.8m / Total Assets 372.7m |
| warn (B) unusual magnitude: -1.96 — check mapping/units |
| (C) -0.13 = EBIT TTM -51.9m / Avg Total Assets 414.0m |
| (D) -1.80 = Book Value of Equity -734.4m / Total Liabilities 408.5m |
| Total Rating: -6.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 46.68
| 1. Piotroski 0.0pt |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity -0.35 |
| 5. Debt/Ebitda 2.67 |
| 6. ROIC - WACC (= 298.8)% |
| 7. RoE 286.6% |
| 8. Rev. Trend -83.45% |
| 9. EPS Trend -66.23% |
What is the price of RNAC shares?
Over the past week, the price has changed by -12.50%, over one month by -18.20%, over three months by -35.12% and over the past year by -66.88%.
Is RNAC a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RNAC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 35.3 | 430.7% |
| Analysts Target Price | 35.3 | 430.7% |
| ValueRay Target Price | 3.7 | -45% |
RNAC Fundamental Data Overview November 21, 2025
P/E Forward = 25.4453
P/S = 170.4178
P/B = 31.2575
Beta = 0.39
Revenue TTM = 1.09m USD
EBIT TTM = -51.9m USD
EBITDA TTM = -49.0m USD
Long Term Debt = 12.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.88m USD (from shortTermDebt, last quarter)
Debt = 12.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -130.8m USD (from netDebt column, last quarter)
Enterprise Value = 55.1m USD (185.9m + Debt 12.6m - CCE 143.4m)
Interest Coverage Ratio = -12.41 (Ebit TTM -51.9m / Interest Expense TTM -4.18m)
FCF Yield = -124.9% (FCF TTM -68.9m / Enterprise Value 55.1m)
FCF Margin = -6315 % (FCF TTM -68.9m / Revenue TTM 1.09m)
Net Margin = -4398 % (Net Income TTM -48.0m / Revenue TTM 1.09m)
Gross Margin = -1073 % ((Revenue TTM 1.09m - Cost of Revenue TTM 12.8m) / Revenue TTM)
Gross Margin QoQ = -2731 % (prev 100.0%)
Tobins Q-Ratio = 0.15 (Enterprise Value 55.1m / Total Assets 372.7m)
Interest Expense / Debt = -33.16% (Interest Expense -4.18m / Debt 12.6m)
Taxrate = -0.37% (negative due to tax credits) (287.0k / -77.1m)
NOPAT = -52.1m (EBIT -51.9m * (1 - -0.37%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 10.67 (Total Current Assets 147.3m / Total Current Liabilities 13.8m)
Debt / Equity = -0.35 (negative equity) (Debt 12.6m / totalStockholderEquity, last quarter -35.8m)
Debt / EBITDA = 2.67 (negative EBITDA) (Net Debt -130.8m / EBITDA -49.0m)
Debt / FCF = 1.90 (negative FCF - burning cash) (Net Debt -130.8m / FCF TTM -68.9m)
Total Stockholder Equity = -16.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.87% (Net Income -48.0m / Total Assets 372.7m)
RoE = 286.6% (negative equity) (Net Income TTM -48.0m / Total Stockholder Equity -16.7m)
RoCE = 1254 % (out of range, set to none) (EBIT -51.9m / Capital Employed (Equity -16.7m + L.T.Debt 12.6m))
RoIC = 311.0% (negative operating profit) (NOPAT -52.1m / Invested Capital -16.7m)
WACC = 12.23% (E(185.9m)/V(198.5m) * Re(13.06%) + (debt cost/tax rate unavailable))
Discount Rate = 13.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 124.3%
Fair Price DCF = unknown (Cash Flow -68.9m)
EPS Correlation: -66.23 | EPS CAGR: -45.40% | SUE: -0.35 | # QB: 0
Revenue Correlation: -83.45 | Revenue CAGR: -67.31% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.91 | Chg30d=-0.058 | Revisions Net=+2 | Analysts=5
EPS next Year (2026-12-31): EPS=-2.58 | Chg30d=-0.710 | Revisions Net=-1 | Growth EPS=-33.7% | Growth Revenue=-73.6%
Additional Sources for RNAC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle